Clinical Trial: Oromucosal Oxytocin and Vasopressin Modulation of Emotional Face Attention

U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07838493) titled 'Oromucosal Oxytocin and Vasopressin Modulation of Emotional Face Attention' on Sept. 16.

Brief Summary: The goal of this clinical trial is to learn how 24 IU oxytocin (OT) and 24 IU arginine vasopressin (AVP), administered through the oral mucosa, affect attention to emotional faces and related brain activity in healthy adults. The study will compare OT and AVP with a placebo (PLC).

The main questions it aims to answer are:

1. Does oromucosally administered oxytocin produce a behavioral pattern of modulation of top-down and bottom-up attention to emotional faces that is qualitatively consistent with previously reported intranasal...